Heska Fourth Quarter and Full Year 2018 Results and Conference Call Scheduled for February 26, 2019

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and year-end 2018 financial results in a press release on Tuesday, February 26, 2019 before the market opens and to host a conference call on the results at 9 a.m. MT / 11 a.m. ET on the same day.

LOVELAND, Colo., /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and year-end 2018 financial results in a press release on Tuesday, February 26, 2019 before the market opens and to host a conference call on the results at 9 a.m. MT / 11 a.m. ET on the same day.

To access the conference call:

From within the United States, please dial 1-800-289-0438
From outside of the United States, please dial 1-323-794-2423
Reference Conference ID: 3028968

The conference call will be webcast live from the Company’s website on www.heska.com.

A telephonic replay will be available beginning at 2 p.m. ET and continue through 11:59 p.m. ET on Tuesday, March 5, 2019. The webcast will be archived on www.heska.com for 90 days.

To access the replay:

From within the United States, please dial 1-844-512-2921
From outside the United States, please dial 1-412-317-6671
Reference Replay Pin Number: 3028968

About Heska
Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through two business segments; Core Companion Animal Health (“CCA”) represents approximately 85% of revenues, and Other Vaccines, Pharmaceuticals and Products (“OVP”) segment represents approximately 15% of revenues. CCA segment includes Point of Care Laboratory testing instruments and consumables, primarily under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes private label vaccine and pharmaceutical production under third party agreements and channels, primarily for herd animal health. For further information on Heska and its products, visit www.heska.com.

Cision View original content:http://www.prnewswire.com/news-releases/heska-fourth-quarter-and-full-year-2018-results-and-conference-call-scheduled-for-february-26-2019-300786470.html

SOURCE Heska Corporation


Company Codes: NASDAQ-SMALL:HSKA
MORE ON THIS TOPIC